Refine your search

Search Results within category "Neurology"

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

Search all categories

Suggestions within category "Neurology"


3 Study Matches

Spoken communication in people with ALS

This is a zoom-based research study on how people with ALS can improve verbal communication. In this study, you will first be asked to complete a hearing test and a short demographic questionnaire. After that, you will do one of two tasks depending on the condition you are assigned to. In one of the tasks, you would listen to recorded speech and indicate what the person in the recording said. In the other condition, you would play an interactive game with another participant. In the second condition, you would be interacting via Zoom to complete a task together and your speech will be recorded.
Elizabeth Krajewski at EZR16@psu.edu
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
native speaker of American English
have good hearing
between 18 and 90 years of age
No identified speech, language, learning or cognitive disorders
Exclusion Criteria:
non-native speaker of American English
Not good hearing
under 18 or over 90 years of age
have identified speech, language, learning or cognitive disorder
Neurology
  Email this study information to me
  Contact the study team

Site for HEALEY ALS Platform Trial - Master Protocol

The HEALEY ALS Platform Trial is a multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS. The trial is designed as a perpetual platform trial. This means that there is a single Master Protocol determining the conduct of the trial.
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT04297683
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Diagnosed with amyotrophic lateral sclerosis (ALS)
Slow vital capacity (SVC) at least 50% predicted
Time since onset of weakness due to ALS within 36 months
Able to swallow pills and liquids
Exclusion Criteria:
Exposure at any time to any gene therapies under investigation for the treatment of ALS
Clinically significant unstable medical condition (other than ALS) that would pose a risk to you
Neurology
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Site for Therapy in Amyotrophic Lateral Sclerosis (TAME)

This is a phase IIB multi-centered, double blind, placebo controlled study to assess the safety and efficacy of a medication called memantine in people with ALS. This study is designed to validate the preliminary data that suggests memantine can slow down the course of ALS and also to determine if memantine can improve ALS patients who have characteristics of frontotemporal dementia.
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT02118727
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Age 18-85
Diagnosed with amyotrophic lateral sclerosis (ALS)
ALS Functional Rating Scale (ALSFRS-R) score > 25
Has a caregiver willing to help with study activities
Exclusion Criteria:
Forced vital capacity (FVC) ≤ 60% predicted
ALS-related weakness for more than 3 years
History of liver disease
Kidney failure
Neurology
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA